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Abstract
Objective—Our goal was to identify phosphorylation sites that regulate serum response factor
(SRF) activity to gain a better understanding of the signaling mechanisms that regulate SRF’s
involvement in smooth muscle cell (SMC)-specific and early response gene expression.
Methods and Results—By screening phosphorylation deficient and mimetic mutations in SRF
−/− ES cells, we identified T159 as a phosphorylation site that significantly inhibits SMC-specific
gene expression in an ES cell model of SMC differentiation. This residue conforms to a highly
conserved consensus cAMP-dependent protein kinase (PKA) site, and in vitro and in vivo labeling
studies demonstrated that it was phosphorylated by PKA. Results from gel shift and chromatin
immunoprecipitation assays demonstrated that T159 phosphorylation inhibited SRF binding to SMC-
specific CArG elements. Interestingly, the myocardin factors could at least partially rescue the effects
of the T159D mutation under some conditions, but this response was promoter specific. Finally, PKA
signaling had much less of an effect on c-fos promoter activity and SRF binding to the c-fos CArG.
Conclusions—Our results indicate that phosphorylation of SRF by PKA inhibits SMC-specific
transcription suggesting a novel signaling mechanism for the control of SMC phenotype.
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Introduction
Smooth muscle cells (SMC) phenotypic modulation plays an important role in the progression
of several prominent cardiovascular diseases, including atherosclerosis, hypertension, and
restenosis 1. While it is well known that this process is controlled by local environmental cues
(see 2 for review), the precise signaling mechanisms that regulate this process are unclear.
Extensive evidence indicates that serum response factor (SRF), is a critical transcriptional
regulator of SMC differentiation maker gene expression 3-8. However, because SRF is a
ubiquitously expressed gene that also regulates early response and cardiac- and skeletal muscle-
specific gene expression (see 9 for review), it is clear that additional mechanisms are involved.
The identification of the myocardin family of transcription factors (myocardin and the
Myocardin-Related-Transcription Factors, MRTF-A and MRTF-B) was a particularly
important advance because these SRF co-factors strongly transactivate SMC-specific gene
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expression (see 10 for review). Importantly, knock-out studies in mice have demonstrated that
myocardin and MRTF-B are required for the differentiation of specific SMC sub-types while
MRTF-A is required for the expression of SM α-actin that occurs in mammary epithelial cells
during lactation. 10 Early studies also demonstrated that SRF is phosphorylated at multiple
residues just N-terminal to the DNA binding domain by several kinases including casein kinase
II, CaM kinase IV, and MAPKAP kinase 2 11-17. Phosphorylation of these sites (especially
Ser 103) increased SRF affinity for the c-fos CArG. However, because SRF phosphorylation
had only marginal effects on SRF’s ability to stimulate c-fos expression and because SRF
phosphorylation was not altered by serum stimulation 18, the physiologic significance of these
findings were unclear.
A more recent study indicates that SRF phosphorylation may regulate SMC differentiation
marker gene expression. Iyer et.al demonstrated that SRF was phosphorylated at S162 by PKC-
α and that this modification attenuated SRF-dependent cardiac and SM α-actin promoter
activity by inhibiting SRF binding to CArG elements 19. Interestingly, SRF binding to the c-
fos CArG was not significantly affected by this mechanism because of the stabilizing effects
of Elk-1 within the ternary complex.
To better examine the role of SRF phosphorylation on SMC differentiation marker gene
expression we have screened a variety of SRF phosphorylation mutants in an SRF −/− ES cell
model of SMC differentiation. Our results suggest that SRF is phosphorylated at T159 by
cAMP-dependent kinase (PKA), and that this phosphorylation inhibits SMC-specific
transcription by inhibiting SRF binding to the CArG elements within the SMC-specific
promoters.
Materials and Methods
Plasmids and SRF mutations
SRF mutations (see figure 1) were generated using the QuikChange mutagenesis kit
(Stratagene) or sequence overlap extension. All SRF constructs were subcloned into flag-
tagged pcDNA3.1 for mammalian expression or pGEX-4T1 (Amersham) for the generation
of GST-fusions. Please see supplemental methods for more detailed protocols.
Cell culture, transfections, and promoter assays
The SRF −/− embryonic stem cells were a generous gift from Alfred Nordheim; (Tubingen
University, Germany) and their culture and differentiation have been previously described
20-22. SM α-actin and SM22 message levels were measured by quantitative RT-PCR from RNA
isolated at day 0, 3, and 6 of the differentiation protocol. The primary rat aortic SMC cell
cultures, transient transfections, and promoter luciferase assays have been previously described
23. Statistical comparisons between groups were made using the 2-tailed Student’s t test with
statistical significance accepted at p<0.05.
Gel shift analyses
Flag-tagged SRF and myocardin factors were translated in vitro using the TnT kit (Promega).
Binding reactions contained 1μL SRF, 2μL of myocardin factor, 20,000 cpms of 32P-labeled
oligonucleotide probe, and 0.20μg dIdC in binding buffer (10mM Tris, pH 7.5, 50mM NaCl,
100mM KCl, 1mM DTT, 1mM EDTA, 5% glycerol). For supershifts, 1μl of anti-flag antibody
(Sigma) was added after the first 20 min of incubation.
Phosphorylation assays
GST-SRF fusion proteins were purified from BL21 bacterial lysates using glutathione
sepharose (Amersham Biosciences). For in vitro kinase reactions 0.08 μg of purified
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constitutively active PKA (New England BioLabs) or 8-pCPT-cGMP-stimulated PKG-Iα
(Promega) was incubated with 2μg GST-SRF in 25μL kinase buffer (50mM Tris, 10mM
MgCl2, 200μM ATP, and 10μCi γ32P-ATP). For in vivo labeling, full length Wt or T159A
flag-tagged SRF variants were expressed in Cos-7 cells. Following washing in phosphate-free
media, cells were incubated with 1mCi ortho 32P for 2h and then treated with 20μM forskolin
for 2.5h or 100μM 8-pCPT-cGMP. SRF was immunoprecipitated from RIPA lysates using
anti-flag agarose beads (Sigma). Phosphorylation assays in SMC were mostly similar except
that endogenous SRF was immunoprecipiatated using an anti-SRF Ab (Santa Cruz).
Chromatin immunoprecipitation assays
ChIP assays were performed according to the X-ChIP protocol (Abcam). In brief, cells were
fixed for 10 min in 1% formaldehyde, placed in lysis buffer (50mM TrisHCl (pH 8.0), 10mM
EDTA, 1% SDS), and then chromatin was sheared into 500 bp to 1000 bp fragments by
sonication. Equal amounts of sample were immunoprecipitated with 2.5μg of anti-SRF (Santa
Cruz), or anti-flag (Sigma) Ab. ChIP PCRs were performed using Red Taq ReadyMix (Sigma)
using primers that were previously described 24. To control for non-specific binding,
immunoprecipitations were also performed in the absence of primary Ab (see supplemental
figure 1 for results).
Results
Identification of T159 as a potential phosphorylation site that inhibits SRF activity
Because little is known about the effects of SRF phosphorylation on SMC-specific
transcription, we decided to screen SRF phosphorylation mutations for their ability to alter
SMC-specific promoter activity when expressed in SRF −/− ES cells. SRF −/− ES cells have
been shown to be stable when grown in LIF containing media and to have similar proliferation
rates to Wt ES cells 25. However, they have an impaired immediate early growth response and
do not express SRF-dependent muscle specific markers such as cardiac-, skeletal-, and SM α-
actin 21,22. As expected, the SM22 and SM α-actin promoters were virtually inactive in SRF
−/− ES cells but were strongly stimulated (by 12 and 50 fold, respectively) by co-transfection
of Wt SRF (figure 1b).
Based upon previous reports on SRF phosphorylation, we generated phosphorylation deficient
(T/S to A) and phospho-mimetic (T/S to D/E) mutations to the residues shown in figure 1a and
expressed these SRF variants in SRF −/− ES cells. In excellent agreement with a previous study
by Iyer et.al. 19, the S162E phosphomimetic dramatically inhibited the activity of both SMC-
specific promoters (fig 1c) providing significant validation of our screening approach. The
phosphomimetic mutation T159D also completely inhibited SRF’s effects on the SM α-actin
promoter and reduced SM22 promoter by about 60%. The c-fos promoter exhibited relatively
high basal activity in the SRF −/− ES cells and was only stimulated 4 fold by expression of Wt
SRF suggesting that its activity was less dependent upon SRF. Nevertheless, SRF-dependent
activation of the c-fos promoter was attenuated by the T159D and S162E mutations. Except
for the T103A mutation, which inhibited SRF-dependent activation of the SM22 and SM α-
actin promoters by 40–50%, none of the other SRF phosphorylation variants tested had major
effects on SRF activity in this model that were not accounted for by differences in SRF
expression levels (data not shown).
T159 was phosphorylated by protein kinase A
Given the novelty and efficacy of the T159D SRF mutation, we wanted to delineate the
molecular mechanisms involved in this effect. Sequence analysis revealed that T159 conforms
to a consensus phosphorylation site for cAMP and cGMP-dependent protein kinases, RRXS/
T (fig 2a). As a first step to determine whether PKA or PKG could phosphorylate T159, we
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performed in vitro kinases assays. A GST fusion protein containing the N-terminal third of
SRF (AA1–203) was incubated with purified active PKG or PKA. As shown in figure 2b, both
of these kinases strongly phosphorylated the Wt construct and this phosphorylation was
dramatically inhibited by the T159A mutation. To test whether these kinases could
phosphorylate SRF in vivo, we transfected full length flag-tagged SRF into Cos-7 cells and
activated PKA or PKG by treatment with forskolin or 8-pCPT-cGMP, respectively. Since
Cos-7 cells express very low levels of PKG, the cells to be treated with 8-pCPT-cGMP were
co-transfected with PKG. As shown in figure 2c, treatment of cells with forskolin resulted in
a significant increase in 32P incorporation in SRF immunoprecipitants and this increase was
completely abrogated by the T159A mutation. Activation of PKG failed to significantly
increase SRF phosphorylation even though these conditions lead to substantial phosphorylation
of the PKG substrate VASP (data not shown). To test whether SRF was phosphorylated by
PKA in SMC, we treated 32P labeled primary rat SMC cultures with forskolin and
immunoprecipitated endogenous SRF. Although SRF was phosphorylated to some extent
under basal conditions, activation of PKA increased this signal (fig 2d). Taken together these
results indicate that T159 is a target for PKA in SMC.
SRF T159D had promoter-specific effects on myocardin factor transactivation
Since SMC differentiation marker gene expression is regulated mainly by SRF’s interaction
with the myocardin family of cofactors, we next tested the functional significance of the SRF
T159 phosphomimetic on SM α-actin and SM22 transactivation by these factors. As shown in
figure 3a, expression of myocardin factors in SRF −/− ES cells strongly increased SM α-actin
promoter activity only in the presence of Wt SRF and the T159D mutation almost completely
inhibited this response. Interestingly, as shown in 3b, the T159D mutation had no effect on
SM22 promoter activity when co-expressed with the myocardin factors suggesting that the
effects of this mutation could be rescued under some circumstances. The S162E mutation
strongly inhibited both promoters under these conditions.
Phosphorylation of T159 inhibited SRF-CArG binding
T159 is located within the amphipathic αI helix of the SRF MADS box that interacts with the
CArG element. It lies on the same helical face as S162, and like S162, has been shown to
interact with nucleotides flanking the CArG sequence 26,27. Given that S162 phosphorylation
inhibited SRF-CArG binding 19, we hypothesized that the inhibitory effect of the T159D
mutation on SMC-specific transcription was due to a similar mechanism. To test this, we
measured the binding of Wt SRF and SRF phosphorylation variants to CArG elements using
gel shift assays. As shown in the left panel of figure 4a, incubation of in vitro translated Wt
flag-tagged SRF with the SM α-actin intronic CArG resulted in a prominent complex that was
supershifted by the addition of anti-flag Ab. SRF binding was slightly reduced by the T159A
mutation but was completely inhibited by both the T159D and S162E mutations (lanes 4 And
5). As shown in lanes 6–13 the addition of myocardin or ΔNMRTF-A resulted in the formation
of a ternary complex with Wt SRF, but not with the T159D or S162E SRF variants.
Interestingly, the results of gel shift assays with the SM22 far CArG were slightly different
(Fig 4a, right panel). First, the T159A mutation had much less of an effect on SRF binding and
myocardin factor complex formation. More importantly, the presence of myocardin could
partially restore binding of the T159D variant to the SM22 far CArG (lane 8). The presence of
ΔNMRTF-A also resulted in a ternary complex (lane 12) that was more clearly visible after
slightly longer exposure times. These data support previous studies from our lab indicating
that differences in CArG and/or CArG flanking sequence have important effects on CArG/
SRF/myocardin factor ternary complex formation 28 and indicate that SRF phosphorylation
may have preferential effects on certain CArG-dependent genes. In addition, these data may
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explain the ability of myocardin factor over-expression to rescue the effects of the T159D
mutation on SM22 promoter activity.
To test whether T159 phosphorylation affected SRF binding in vivo, we performed chromatin
immunoprecipitation (ChIP) assays in 10T1/2 cells over-expressing Wt, T159A, and T159D
SRF variants. In this assay, if SRF is present at a CArG-containing promoter region upon
fixation, then these promoter fragments would be detected by PCR in SRF immunoprecipitates.
As shown in figure 4b (and quantified at right), the binding of the T159A variant to the CArG-
containing regions of the SM α-actin, SM22, and SM MHC promoters was significantly
stronger than that observed with Wt SRF even though these proteins were expressed at identical
levels (Fig 4E). Consistent with our gel shift data, binding of the T159D SRF variant to all of
the SMC-specific promoters was significantly weaker than Wt. Binding of the T159A SRF
variant to the SM MHC promoter in 10T1/2 cells was resistant to the effects of forskolin (Fig
4d), directly implicating T159 phosphorylation by PKA in this mechanism. Importantly, we
also used ChIP assays in primary SMC to demonstrate that the interaction of endogenous SRF
with the SMC-specific promoters was inhibited by forskolin treatment (figure 4c).
Interestingly, the phosphorylation mutations or forskolin treatment had no significant effect
on SRF binding to the CArG-containing region of the c-fos promoter.
The T159D mutation inhibited SMC differentiation of ES Cells and SMC
The results presented so far indicate that SRF is phosphorylated by PKA at T159 and that this
phosphorylation can inhibit SMC-specific promoter activity. To further test this regulatory
mechanism on SMC differentiation, we used a previously described monolayer ES cell model
in which endogenous SMC differentiation marker gene expression is induced by removal of
LIF and addition of retinoic acid 20-22. As expected, SMC differentiation marker gene mRNAs
were not detected in SRF −/− ES cells transfected with empty expression vector at any time-
point of the differentiation protocol. In contrast, transfection of Wt SRF into SRF −/− ES cells
induced endogenous SM α-actin and SM22 message levels by 55 and 20 fold, respectively,
and these levels were further increased at day 3 and day 6 of the differentiation protocol (figure
5a). The T159D and S162E mutations significantly reduced SM α-actin and SM22 message
levels at day zero and prevented any further increase in message levels at the later time-points
(figure 5b). Interestingly, the T159A mutation actually increased SM22 message levels
suggesting at least some basal SRF phosphorylation under these conditions.
Finally, we performed several experiments to test whether PKA-dependent phosphorylation
of SRF affected SMC-specific transcription in mature SMC. As shown in figure 6b, forskolin
dramatically inhibited SM α-actin and SM22 promoter activity in primary SMC cultures but
had only minor effects on c-fos. We also tested whether the T159D functioned as a dominant
negative in SMC. As previously demonstrated by us and others, expression of Wt SRF in SMC
led to a dose-dependent inhibition of SM α-actin promoter activity most likely due to the
squelching of transcription factors or co-factors required for promoter activity. Importantly the
inhibitory effects of the T159D mutation were significantly greater than Wt providing
additional evidence that this signaling mechanism plays a role in the regulation of SMC
phenotype.
Discussion
Extensive evidence indicates that SRF plays a critical role in the regulation of SMC-specific
and early response growth gene expression, and a major goal of these studies was to identify
signaling mechanisms that regulate SRF’s involvement in these disparate gene programs.
Although many kinases have been identified that phosphorylate SRF, the significance of these
modifications in regard to the regulation of SMC-specific gene expression are somewhat
unclear. Thus, in the present study we used a relatively unbiased approach to identify
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phosphorylation sites on SRF that regulate its ability to drive SMC-specific expression. By
expressing phosphorylation mutants in SRF −/− ES cells, we identified T159 as a
phosphorylation site that negatively regulates SRF activity. T159 was phosphorylated by PKA
in vitro and in vivo, and gel shift and ChIP assays strongly suggest that this phosphorylation
regulates SRF’s interaction with SMC-specific CArG elements.
Several studies have characterized SRF’s interaction with CArG-containing oligonucleotides,
and the major contacts between SRF and DNA are between the basic residues within the SRF
αI helix and the core CArG sequence 26,27,29. However, as shown in the original crystal
structure of the core SRF dimer bound to DNA 26, T159 and S162 of one SRF αI helix contact
a residue on the 5′ flank of the CArG element 26. Interestingly, Mo et al. demonstrated that the
presence of the SRF accessory protein, SAP-1, within the ternary complex significantly
increased SRF contacts with the CArG flanking regions of the c-fos SRE including additional
interactions between S162/T159 on the second αI helix with a thymine residue to the 3′ side
of the CArG box 27. Thus, the inhibitory effects of the T159 and S162 phosphorylation observed
in the present studies are consistent with the importance of these residues for SRFs interaction
with DNA. Interestingly, a similar crystal structure study on the SAP-1-containing ternary
complex by Hassler et. al. did not detect an interaction between T159 and CArG flanking
sequence 29. Although the precise nature of this discrepancy is somewhat unclear, the CArG-
containing oligonucleotide used by this group was substantially different suggesting that
sequence variations within or flanking the CArG element may play a role in determining SRF
conformation in the ternary complex. Our demonstration that the myocardin factors could
specifically rescue the effects of the T159D mutation on SRF binding to and activation of the
SM22 promoter indicates that the myocardin factors alter SRF-CArG interactions and supports
the idea that sequence variation within the CArG or CArG flanking regions plays an important
role in this mechanism.
The ability of the T159A mutation to enhance SRF binding in ChIP assays and the observation
that T159A binding in this assay was resistant to forskolin treatment provide additional support
for a direct role for PKA-mediated phosphorylation in the regulation of SRF binding. The
observation that the T159A mutation did not consistently increase SMC-specific transcription
in functional assays suggests that basal levels of T159 phosphorylation are relatively low or
that SRF binding is not rate limiting under the conditions tested. Interestingly, the T159A had
negative effects on transcriptional activity in some experiments and on DNA binding in gel
shift assays. Similar effects were seen with the 162A mutation (by us and by Iyer et.al. 19)
perhaps suggesting that these S/T residues in their non-phosphorylated form may be important
for SRF function.
Activation of PKA has many affects in the cell and its ability to inhibit SRF binding to SMC-
specific CArG elements may only partially explain its effects on SMC-specific transcription.
Indeed, it is well known that PKA antagonizes RhoA-dependent signaling in a variety of cell
types (including SMC) resulting in inhibition of actin stress fiber formation 30,31. Since we
have shown that actin polymerization positively regulates SMC-specific transcription by
enhancing the nuclear localization of the MRTFs 23,28,32, it PKA may also inhibit SMC-
specific transcription by this mechanism. Interestingly, PKA and RhoA signaling also have
antagonistic effects on SMC contractility, and we postulate that these pathways may act in
combination to couple agonist-induced changes in SMC contractility to subsequent changes
in contractile protein gene expression.
Several lines of evidence from the current study indicated that T159 phosphorylation has less
of an effect on c-fos promoter activity. First, the overall activity of the c-fos promoter was less
dependent upon the presence of SRF. Second, SRF binding to the c-fos SRE in ChIP assays
was not affected by the T159D mutation or forskolin treatment. These results likely reflect the
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stabilization of SRF binding to the c-fos SRE by the TCFs 19. Finally, PKA treatment of SMC
resulted in a relatively small reduction in c-fos promoter activity. Because the c-fos promoter
is also regulated by a cAMP response element, the positive effects of PKA on CREB may limit
the negative effects of PKA on SRF. While most previous studies suggest that PKA activation
inhibits SMC proliferation (see 33 for review), our data suggest that it may be more important
for down regulating the SMC differentiation gene program. Clearly, SMC growth and
differentiation are not mutually exclusive 2 and PKA signaling may have independent effects
on these important SMC parameters.
Our results also have important implications on control of SMC phenotype by environmental
cues that regulate cAMP levels. A previous study by Davis et. al. demonstrated that activation
of PKA in rat aortic SMC inhibited while dominant negative PKA enhanced SRF-dependent
transcription 34. Subsequently, this group showed that activation of PKA by the Gαs-coupled
agonists, isoproterenol and ATP, resulted in a decrease in endogenous SMC differentiation
marker gene expression 35. In contrast, Fetalvero et al. demonstrated in human aortic SMC that
the prostacyclin analog, iloprost, enhanced SMC differentiation marker gene expression by a
mechanism that was dependent upon PKA 36. Although the discrepancy between these studies
could be explained by species differences, it is also possible that agonist-specific differences
in the level, timing, or localization of PKA activation by these agonists may also play a role.
Of interest, genetic deletion of the inhibitory RIα subunit of PKA in the mouse (which led to
constitutive PKA activity) resulted in defective mesoderm formation 37, a phenotype very
similar to that observed in SRF knock out mice 22,25.
Our findings are somewhat contrary to an earlier study demonstrating that a T159
phosphomimetic enhanced cardiac α-actin promoter activity in CV-1 cells 38. In the original
report of these results, the T159D mutation did not affect SRF binding, and the positive effects
of the T159D variant were attributed to increased association of SRF with additional
transcription factors such as GATA-4 and Nkx2.5. However, during the completion on of the
current study these authors published an erratum to this manuscript that was prompted by the
discovery of a sequencing error in their T159D construct (Biochemistry. 2008 Feb 5;47(5):
1464). Although they now conclude that the T159D mutation inhibits SRF binding, they
confirmed that this mutation increases cardiac α-actin-promoter activity in CV-1 cells. ES cells
grown in monolayer culture do not express Nkx2.5 and Gata-4 39,40 and the lack of this (or
some other) positive transcription factor interaction could help explain this discrepancy. It is
also important to note that these authors demonstrated that T159 was a possible substrate for
myotonic dystrophy protein kinase (DMPK) and PKCα. In the current study, we focused on
the role of PKA because it had previously been shown to have negative effects on SMC-specific
transcription. While, we cannot rule out that DMPK and/or PKCα phosphorylate SRF at T159,
our data indicate that such a modification would inhibit SMC-specific transcription.
In summary, the results from the present study indicate that phosphorylation of SRF at T159
by PKA inhibits SMC-specific transcription by inhibiting SRF’s interaction with CArG
elements. The promoter specific effects of this modification in the presence of the myocardin
factors suggest that it may be an important mechanism by which SRF differentially regulates
the many genes that are CArG-dependent. Thus, it will be critical to further investigate the role
of PKA signaling on SMC phenotype and to identify the consequences of this modification on
SMC function.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The phosphomimetic T159D mutation negatively regulated SRF-dependent SMC-specific
transcription
A) Schematic of SRF functional domains and phosphorylation sites tested in these studies.
B) SRF was transfected into SRF −/− ES cells along with SM22, SM α-actin, or c-fos promoter/
luciferase constructs. Luciferase activity was measured 24h post-transfection and expressed
relative to that measured in the presence of an equal amount of empty expression vector. C)
The indicated SRF variants and promoter-reporter constructs were co-transfected into ES cells.
Luciferase activity after 24h was measured and is expressed relative to empty expression vector
set to 1. *p<0.05 versus Wt SRF D) Western blot showing expression levels of the SRF variants
in ES cells 24h post-transfection.
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Figure 2. PKA phosphorylated SRF T159 in vitro and in vivo
A) SRF sequence conservation near the consensus PKA/PKG phosphorylation site at T159
B) GST-SRF fusions (AA 1–203) containing Wt or T159A protein sequence were incubated
with γ32P-ATP in the presence of active PKA or PKG for 15 min. Following removal of
unincorporated label, samples were separated on an SDS-Page gel and exposed to film. C)
Cos-7 cells expressing flag-tagged Wt and T159A SRF were incubated with 1mCi ortho 32P
for 2h and then stimulated with 20μM forskolin or 100μM 8-pCPT-cGMP for 2h. SRF was
then immunoprecipitated from RIPA lysates using anti-flag agarose. Following washing
immunoprecipitants were run on an SDS-Page gel, transferred to nitrocellulose, and exposed
to film. D) Endogenous SRF was immunoprecipitated from primary SMCs labeled with
ortho 32P and then treated with FSK for the indicated times. Immunoprecipitants were run on
an SDS-Page gel, transferred to nitrocellulose, and exposed to film.
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Figure 3. Myocardin factor over-expression rescued the inhibitory effects of the T159 mutation in
a promoter-specific fashion
SM α-actin (A) and SM22 (B) promoter luciferase constructs were co-transfected into SRF −/
− ES cells along with the indicated SRF variant and myocardin factor. Luciferase activity was
measured at 24h. *p<0.05 versus Wt SRF.
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Figure 4. Phosphorylation of T159 inhibited SRF binding to the SMC-specific CArGs
A) Radiolabeled oligonucleotide probes containing either the SM α-actin intronic CArG (left
panel) or the SM22 far CArG (right panel) were incubated with the indicated SRF variant in
the absence or presence of myocardin or ΔNMRTF-A. All proteins were in vitro translated and
the total amount of TnT protein in each reaction was maintained by the addition of
unprogrammed lysate. After 30 min binding reactions were run on a 5% non-denaturing gel,
transferred to filter paper, and visualized by autoradiography. For supershifts (lane 1), 1μL of
anti-flag antibody was added after 20 minutes of incubation. B) 10T1/2 cells were transfected
with the Wt, T159A, or T159D SRF variant. After 48h cells were processed for ChIP assays
by standard protocols (see methods for more details). PCR reactions were performed on
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immunoprecipitants using primers spanning the SM α-actin intronic CArG, the SM22 far
CArG, a SM MHC 5′ CArG, and the c-fos CArG. Quantification of 3 separate ChIp assays is
shown in the right panel. C) SMCs grown in 10% FBS were treated with 20μM forskolin for
the indicated time before processing for ChIP assays. * p<0.05 versus vehicle treated. D)
10T1/2 cells expressing the T159 SRF variant were treated with forskolin for 1h before
processing for ChIP assays. E) Western blot of SRF variant expression in 10T1/2 cells.
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Figure 5. The T159D mutation inhibited endogenous SMC marker gene expression in an ES cell
model of SMC differentiation
A) SRF −/− ES cells were transfected with Wt SRF. After 24 h cells were placed in
differentiation media (minus LIF, plus 500nM retinoic acid) for 0, 3, and 6 days. SM α-actin
and SM22 message levels were measured by quantitative PCR. * p<0.05 versus plus empty
expression vector. B) SRF −/− ES cells expressing the indicated SRF variants were subjected
to the SMC differentiation protocol. SM α-actin and SM22 mRNA levels measured at 0, 3, and
6 d are expressed relative to Wt SRF set to 1. * p<0.05 versus Wt SRF
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Figure 6. PKA activation inhibited SM α-actin and SM22 promoter activity in primary SMC
A) Primary SMCs were transfected with SM α-actin, SM22, or c-fos promoter luciferase
constructs. Luciferase activity was measured after treatment with 20μM forskolin for 9h. *
p<0.05 versus vehicle. B) Primary SMC cultures were co-transfected with SM α-actin-
luciferase and increasing concentrations of Wt or T159D SRF. * p<0.05 versus same
concentration of Wt SRF.
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